Matwings Technology, a provider of an AI-driven protein design platform, announced the successful completion of Series A funding rounds.
The funding amount was not disclosed.
Qiming Venture Partners led the investment round.
With fresh funds, Shanghai Matwings Technology intends to scale up its protein design platform.
Matwings, founded in 2021 by an elite team from Shanghai Jiao Tong University, is one of the earliest companies to focus on AI protein models.
Since its inception, Matwings is pioneering a new frontier in protein engineering with its proprietary AI-based general protein design platform, AccelProtein, which directly predicts protein functionality beyond the structural data. By predicting functionality, AccelProtein offers a new approach to acquiring high-functioning proteins.
To date, Matwings has successfully engineered more than 30 proteins either proprietary or co-developed with its stakeholders, and more than 40 ongoing projects across various applications in pharmaceutical industries and synthetic biology industries, e.g. key enzymes and proteins for CMC, innovative Biologics, synthetic biology and more.